Daewoong Pharmaceutical 2026 Q1: Revenue Growth Continues, Operating Profit Declines, New Technology Acquisition and Pipeline Strength

2026 Q1 separate revenue KRW 335.7B (up 6.2% YoY), operating profit KRW 27.4B (down 34.7%).
Consolidated revenue KRW 377.8B, operating profit KRW 22.2B, net profit KRW 25.5B.
R&D expenditure KRW 55.2B (16.44% of revenue), continuous investment in new drug pipeline.
Ongoing second trial of trade secret lawsuit with Medytox; related provision of KRW 56.8B recognized.
New ERA platform technology acquisition (up to $239M) and INV-008 license-in contract (up to KRW 662.5B).
Credit rating A+ (stable) maintained, net debt ratio 38.88%.
Pharmaceutical manufacturing segment operating profit KRW 23.9B, down from KRW 42.1B in previous quarter.
Continued global sales expansion of key products: Nabota, Fexuclue, Envlo.